I Was Wrong: We Can’t Skip Phase 3 Vaccine Trials - Forbes

On the benefit side, my article assumed that we could quickly make millions of doses available before Phase 3 trials completed.

We can and should ramp up production of vaccines before Phase 3 trials are over–and several manufacturers are doing just that, with government support.

But these vaccines aren’t available in large quantities yet, and by the time they are, Phase 3 trials will be much further along.

I'm the Bloomberg Distinguished Professor of Biomedical Engineering, Computer Science, and Biostatistics at Johns Hopkins University.

I'm the Bloomberg Distinguished Professor of Biomedical Engineering, Computer Science, and Biostatistics at Johns Hopkins University.

From 2005-2011 I was the Horvitz Professor of Computer Science and Director of the Center for Bioinformatics and Computational Biology at the University of Maryland, College Park.